Innate and adaptive immunity: the understudied driving force of heart valve disease
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Calcific aortic valve disease (CAVD), and its clinical manifestation that is calcific aortic valve stenosis, is the leading cause for valve disease within the developed world, with no current pharmacological treatment available to delay or halt its progression. Characterized by progressive fibrotic remodelling and subsequent pathogenic mineralization of the valve leaflets, valve disease affects 2.5% of the western population, thus highlighting the need for urgent intervention. Whilst the pathobiology of valve disease is complex, involving genetic factors, lipid infiltration, and oxidative damage, the immune system is now being accepted to play a crucial role in pathogenesis and disease continuation. No longer considered a passive degenerative disease, CAVD is understood to be an active inflammatory process, involving a multitude of pro-inflammatory mechanisms, with both the adaptive and the innate immune system underpinning these complex mechanisms. Within the valve, 15% of cells evolve from haemopoietic origin, and this number greatly expands following inflammation, as macrophages, T lymphocytes, B lymphocytes, and innate immune cells infiltrate the valve, promoting further inflammation. Whether chronic immune infiltration or pathogenic clonal expansion of immune cells within the valve or a combination of the two is responsible for disease progression, it is clear that greater understanding of the immune systems role in valve disease is required to inform future treatment strategies for control of CAVD development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Burden of valvular heart diseases: a population-based study
Nkomo, V. T., Gardin, J. M., Skelton, T. N., Gottdiener, J. S., Scott, C. G., & Enriquez-Sarano, M. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69208-8 · Cited by 4,881
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841
Flow-mediated endothelial mechanotransduction
Davies, P. F. (1995) · Physiological Reviews · doi:10.1152/physrev.1995.75.3.519 · Cited by 2,802
Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease
Jaiswal, S., Natarajan, P., Silver, A. J., Gibson, C. J., Bick, A. G., Shvartz, E., McConkey, M., Gupta, N., Gabriel, S., Ardissino, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701719 · Cited by 2,683 · cited 1×
“Unexpectedly, CHIP has been strongly associated with cardiovascular mortality and increased of coronary artery disease and progression of mineralization, with carriers four times more likely to experience myocardial infarction than non-carriers.(163,164) Unassociated to traditional cardiovascular risk factors, recent…”
BackgroundMacrophages in the Pathogenesis of Atherosclerosis
Moore, K. J., & Tabas, I. (2011) · Cell · doi:10.1016/j.cell.2011.04.005 · Cited by 2,669
Macrophage plasticity and polarization in tissue repair and remodelling
Mantovani, A., Biswas, S. K., Galdiero, M. R., Sica, A., & Locati, M. (2013) · The Journal of Pathology · doi:10.1002/path.4133 · Cited by 2,384 · cited 1×
“The blockage of IL-17 suggested to decrease plaque size and induce differentiation of M2 macrophages that promote inflammation resolution and secretion of anti-inflammatory cytokines and participates in the induction of Th2 response.(114) IL-17 is increased within CAVD patient plasma correlating with disease progressi…”
BackgroundClonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice
Fuster, J. J., MacLauchlan, S., Zuriaga, M. A., Polackal, M. N., Ostriker, A. C., Chakraborty, R., Wu, C.-L., Sano, S., Muralidharan, S., Rius, C., et al. (2017) · Science · doi:10.1126/science.aag1381 · Cited by 1,536 · cited 1×
“Mutations in either TET2 or DNMT3A are accompanied by increased inflammation due to the activation of the inflammasome complex, raising both IL-6 and IL-1b expressions, further highlighting CHIPs central role in inflammatory disease progression.(166) Mutations associated with CHIP have effects on immune effector cells…”
BackgroundPerforin and granzymes: function, dysfunction and human pathology
Voskoboinik, I., Whisstock, J. C., & Trapani, J. A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3839 · Cited by 1,327 · cited 1×
“Finally, CD8þ cells release serineprotease granzymes and pore-forming perforin into the cleft between the membranes of the CD8þ cell and the target cell, resulting in breakdown of the membrane and targeting the cell for apoptosis.(152) Production of IFNc from this population has been suggested to drive the ectopic val…”
BackgroundNatural Killer Cells: Development, Maturation, and Clinical Utilization
Abel, A. M., Yang, C., Thakar, M. S., & Malarkannan, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01869 · Cited by 1,150
A Randomized Trial of Intensive Lipid-Lowering Therapy in Calcific Aortic Stenosis
Cowell, S. J., Newby, D. E., Prescott, R. J., Bloomfield, P., Reid, J., Northridge, D. B., & Boon, N. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043876 · Cited by 1,146 · cited 1×
“ering drug atorvastatin, attempting to halt or regress calcific aortic stenosis; however, researchers found no significantly beneficial outcome.(171)”
Background
Cited by
Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy
Kraler, S., Blaser, M. C., Aikawa, E., Camici, G. G., & Lüscher, T. F. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab757 · Cited by 281
Self-citationSong, G.-Y., Guo, X.-N., Yao, J., Lu, Z.-N., Xie, J.-H., wu, F., He, J., Fu, Z.-L., & Han, J. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03311-x · Cited by 11
Houessou, U., Zamani, P., Manikpurage, H. D., Li, Z., Gaudreault, N., Dahmene, M., Dagenais, F., Couture, C., Clavel, M.-A., Pibarot, P., et al. (2025) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2025.01.018 · Cited by 11
Metadata
- Authors
- Bartoli-Leonard, F., Zimmer, J., & Aikawa, E.
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-08-25
- Volume
- 117
- Issue
- 13
- Pages
- 2506-2524
- ISSN
- 0008-6363 (ISSN-L)
- 1755-3245
- OpenAlex
- W3194062313
- Cited by
- 81
- References
- 29
- FWCI
- 7.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Innate and adaptive immunity: the understudied driving force of heart valve disease. https://app.cochat.ai/papers/10.1093/cvr/cvab273
- The paper
- Bartoli-Leonard, F., Zimmer, J., & Aikawa, E. (2021). Innate and adaptive immunity: the understudied driving force of heart valve disease. Cardiovascular Research. https://doi.org/10.1093/cvr/cvab273
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.